HTA Dossiers: A Guide to Submissions for NICE, CADTH & ICER
An in-depth guide to HTA dossiers. Explore the evidence requirements, economic models, and submission templates for NICE (UK), CADTH (Canada), and ICER (US).
Back to Articles
Articles tagged with “cost-effectiveness-analysis”
QALYs & ICERs Explained: Core Health Economics Metrics
An educational guide to QALYs and ICERs, the core metrics in health economics. Learn how they measure value and guide cost-effectiveness decisions. Updated April 2026 with NICE's new £25k–£35k/QALY threshold.
QALYs & Quality of Life: Justifying Specialty Drug Costs
Learn how patient quality of life (QoL) data is quantified into Quality-Adjusted Life Years (QALYs) to perform cost-effectiveness analysis for specialty drugs.
How Real-World Data Validates Clinical Trial Assumptions
How real-world data (RWD) and evidence (RWE) validate clinical trial assumptions in post-market economic models. Updated April 2026 with EU JCA, DARWIN EU, FDA finalized RWE guidance, ICH M14 and EHDS developments.
Health Economic Data for Drug Formulary & Reimbursement
Learn how health economic data like cost-effectiveness analysis is used to secure drug formulary placement and reimbursement from payers and HTA bodies.